Charles River Laboratories International, Inc., together with its subsidiaries, operates as an early-stage contract research company, provides drug discovery and preclinical development services worldwide. Segments The company has three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). RMS segment This segment supplies research models to the drug development industry. This segment includes Research Models and Research Model Services. Research Models The company’s Research Models business includes the production and sale of research models. Research Models: A portion of this business includes the commercial production and sale of research models, principally purpose-bred rats and mice for use by researchers. The company provides its rodent models to various clients worldwide, including most pharmaceutical companies, a range of biotechnology companies and many government agencies, hospitals and academic institutions. The company’s research models include standard stocks and strains and disease models, such as those with compromised immune systems, which are in demand as early-stage research tools. The company’s research models include outbred, which are purposefully bred for heterogeneity; inbred, which are bred to be homogeneous; spontaneous mutant, which contain a naturally occurring genetic mutation (such as immune deficiency); hybrid, which are the offspring of two different inbred parents; and other genetically modified research models, such as knock-out models with one or more disabled genes and transgenic models. Certain of the company’s research models are proprietary, disease-specific rodent models used to find new treatments for diseases, such as diabetes, obesity, cardiovascular and kidney disease. The company is also a provider of purpose bred, specific-pathogen-free (SPF) large research models to the biomedical research community. Research Model Services This segment also offers various services designed to support the company’s clients' use of research models in basic research and screening preclinical drug candidates. These services address the need among pharmaceutical and biotechnology companies to outsource the non-core aspects of their drug discovery activities. The company’s services include those which are related to the maintenance and monitoring of research models, and managing research operations for government entities, academic organizations and commercial clients. The company has three service offerings in research models services, such as Genetically Engineered Models (GEMs) and Services (GEMS); Insourcing Solutions; and Research Animal Diagnostic Services. GEMS: The company breeds and maintains research models purchased or purposefully created by its clients for biomedical research activities. The creation of a GEM is a critical scientific event, but it is only the first step in the discovery process. The company provides breeding expertise and colony development, quarantine, health and genetic testing and monitoring, germplasm cryopreservation, and rederivation, including assisted reproduction. The company’s team of project managers is supported by an advanced system Internet Colony Management that allows for real-time data exchange. The company provides these services to clients worldwide, including pharmaceutical and biotechnology companies, hospitals, universities, and government agencies. Insourcing Solutions: The company manages research operations (including recruitment, training, staffing and management services) for government entities, academic organizations, and commercial clients. Research Animal Diagnostic Services: The company monitors and analyzes the health profiles of research models and cell lines used by its clients. The company developed this capability internally to address the diagnostic needs of its own research model business. The company is able to serve as their sole-source testing laboratory, or as an alternative source supporting its clients’ internal laboratory capabilities. DSA segment This segment offers discovery and safety assessment se
charles river laboratories
251 Ballardvale Street
Wilmington, MA 01887
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for CRL.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.